Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough's Japanese subsidiary Schering-Plough K.K. has received marketing approval for Claritin dry syrup 1% in Japan, a once-a-day nonsedating antihistamine for treatment of allergic rhinitis, urticaria and itching associated with skin diseases in patients aged three years and older.
Subscribe to our email newsletter
Additionally, Claritin tablets and Claritin Reditab tablets have been approved for these uses in patients over the age of seven. In Japan, Schering-Plough co-markets the Claritin line of medications with Shionogi & Co.
Claritin is marketed in over 100 countries worldwide and is available in several countries without a prescription. Dry syrup is a unique granule formulation available only in Japan.
Robert Spiegel, chief medical officer and senior vice president, Schering- Plough Research Institute, said: “Claritin dry syrup is an easily administered, long-lasting formulation for treating children as young as age three, and approval of this new formulation provides an important treatment option for pediatric patients in Japan.”